Galante Joseph C 4

What Happened
Joseph C. Galante, a director of Cumberland Pharmaceuticals, received an award of 1,800 shares on March 18, 2026. The award is recorded at $2.80 per share for a total value of $5,040. This transaction is coded as an award/grant (A), i.e., an acquisition rather than a sale.

Key Details

• Transaction date: 2026-03-18; filing date: 2026-03-20 (appears timely under Form 4 rules).
• Transaction type/code: Award/Grant (A).
• Shares acquired: 1,800 at $2.80 per share; total reported value $5,040.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes/notable terms: Filing does not specify vesting, restrictions, or a 10b5-1 plan.

Context
Award grants (code A) are typically part of director compensation plans and represent an acquisition of shares rather than a sale; such grants can indicate alignment with shareholders but are often routine. The dollar value here is modest, so while it is an insider acquisition, it is relatively small in scale.